Envida   Report issue

For profit Phase 4
Founded: Maastricht Netherlands (2014)
Status: No NME R&D (2014)

Organization Overview

First Clinical Trial
2018
NCT03616639
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Envida, Maastricht, The Netherlands

Active Ingredients

Drugs in Phase 4 Trials (2)

morphine (1 trial)

oxycodone (oxycontin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Renal Insufficiency (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 2